We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urinary Biomarkers Perform Better Than Serum Biomarkers in Detection of Specific Diseases

By LabMedica International staff writers
Posted on 02 Nov 2023

The focus in biomarker research has largely been on blood-based markers. More...

Yet, blood markers don't provide a complete picture of clinically relevant indicators. As a result, urine has proved to be a significant and additional source of information for diagnosis. Its diagnostic power, especially for certain conditions, is gaining recognition, sometimes even surpassing that of blood biomarkers. Now, a new study has shed light on the enhanced ability of urinary biomarkers to detect diseases compared to plasma biomarkers.

The study by a group of researchers, including scientists from the Shanghai Changzheng Hospital (Shanghai, China), has revealed that urine biomarkers might be better than serum biomarkers at detecting some illnesses. Blood is a complex mix that remains fairly stable due to the body's homeostatic mechanisms. Urine, on the other hand, varies more because it is a byproduct of kidney filtration and does not need to maintain a stable state. This variability means it can indicate changes occurring in the body more accurately.

During urine production in the kidney's nephrons, biomarkers specific to the urinary system can become more concentrated than in blood. Smaller molecules that aren't reabsorbed after the kidney's filtration become more concentrated in the urine, making them easier to identify. The simplicity and non-invasive nature of collecting urine also make it appealing for biomarker research. Plus, proteins in urine can be preserved for a long time without degrading. Despite these advantages, the researchers recognize hurdles like standardizing urine biomarker tests and expanding the range of illnesses detectable through urine.

“The direct association between urine and the urinary system positions it as a prime area for discovering biomarkers, particularly in the context of urological diseases,” said Dr. Cheng Xue from the Shanghai Changzheng Hospital. “A key takeaway from our findings is the potential for a combined approach, leveraging both urinary and serum biomarkers for a more holistic and personalized strategy for disease diagnosis and management.”

Related Links:
Shanghai Changzheng Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
POC Immunoassay Analyzer
Procise DX
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.